Octocog alfa 2,000unit powder and solvent for solution for injection vials
Requires a prescription from a doctor or prescriber
Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Octocog alfa
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
MHRA licensed products
View all licensed products for Octocog alfa on the MHRA register
Advate 2,000unit powder and solvent for solution for injection vials
Helixate NexGen 2,000unit powder and solvent for solution for injection vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 12 · Randomised trials: 8 · 2007–2026
Showing the 50 most relevant studies, sorted by most relevant.
E. Van Cutsem, M. Tempero, D. Sigal, et al.
Journal of Clinical Oncology, 2020
H. Gisslinger, C. Klade, P. Georgiev, et al.
The Lancet. Haematology, 2020
U. Platzbecker, M. D. Della Porta, V. Santini, et al.
Lancet, 2023
J. Díaz-Manera, P. Kishnani, H. Kushlaf, et al.
The Lancet. Neurology, 2021
Feng X, Zhou X, Sun J, et al.
2025
- Hemophilia A
- Factor VIII
- Hemorrhage
IntroductionInhibitor development is a primary concern for pediatric patients with hemophilia A (HA) undergoing recombinant factor VIII (rFVIII) therapy, yet relevant research is lacking. We aimed to compare the efficacy and safety of standard (SHL) and extended half-life (EHL) rFVIII products in previously treated (PTPs) and untreated (PUPs) pediatric patients with HA.MethodsFollowing PRISMA guidelines, we searched clinical studies from PubMed, Embase, and Cochrane Library. Data were extracted and a single-arm meta-analysis was performed.ResultsThis systematic review included 16 studies involving 1145 patients. Three studies reported changes in annual bleeding rate (ABR); their results displayed no statistically significant difference in ABR changes in pediatric patients with HA after rFVIII treatment. Ten studies reported inhibitor development, nine focused on PUPs. Here, EHL rFVIII showed a proportion of inhibitors at 27.5% (95% confidence interval [CI] 22.6%; 32.6%), and third-generation SHL rFVIII showed a proportion of inhibitors at 36.4% (27.2%; 46.2%), with a high-titer proportion of 20.9% (12.9%; 30.3%) for the latter. Both SHL rFVIII (octocog alfa) and EHL rFVIII (rurioctocog alfa pegol) presented low proportions of inhibitor development. Octocog alfa exhibited the lowest high-titer inhibitor incidence, marked at 12.7% (5.3%; 24.5%). Eleven studies addressed adverse events (AEs), with octocog alfa showing low reported treatment-related AEs at a proportion of 14.5% (6.5%; 26.7%).ConclusionOur analysis revealed that both octocog alfa and rurioctocog alfa pegol showed low inhibitor development, with octocog alfa having few treatment-related AEs. Regular monitoring for inhibitors during rFVIII therapy is important.
Abstract licence: CC BY-NC
J. M. Kirkwood, M. H. Strawderman, M. Ernstoff, et al.
Journal of Clinical Oncology, 2023
B. Cho, J. Lee, Yi-long Wu, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2023
Alberto Tosetto, A. Arnaud, Nana Kragh, et al.
Research and Practice in Thrombosis and Haemostasis, 2023
Annette von Drygalski, Pratima Chowdary, Roshni Kulkarni, et al.
New England Journal of Medicine, 2023
- Coagulants
- Factor VIII
- Hemophilia A
Eric L. Wallace, O. Goker-Alpan, William R. Wilcox, et al.
Journal of Medical Genetics, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
8.4-19.3 hrs
Mechanism
Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation.
Food interactions
None known
Human targets
11 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
8.4-19.3 hrs
Clearance
4.1 mL
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L41025][L36130]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 93 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:22409427
Factor Xa activates pro-inflammatory signaling pathways in a protease-activated receptor (PAR)-dependent manner .
PMID:24041930 PMID:30568593 PMID:34831181 PMID:18202198
Up-regulates expression of protease-activated receptors (PARs) F2R, F2RL1 and F2RL2 in dermal microvascular endothelial cells .
PMID:35738824
Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL6, in cardiac fibroblasts and umbilical vein endothelial cells in PAR-1/F2R-dependent manner .
PMID:30568593 PMID:34831181
Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2, IL6, TNF-alpha/TNF, IL-1beta/IL1B, IL8/CXCL8 and IL18, in endothelial cells and atrial tissues .
PMID:24041930 PMID:35738824 PMID:9780208
Induces expression of adhesion molecules, such as ICAM1, VCAM1 and SELE, in endothelial cells and atrial tissues .
PMID:24041930 PMID:35738824 PMID:9780208
Increases expression of phosphorylated ERK1/2 in dermal microvascular endothelial cells and atrial tissues .
PMID:24041930 PMID:35738824
Triggers activation of the transcription factor NF-kappa-B in dermal microvascular endothelial cells and atrial tissues .
PMID:24041930 PMID:35738824
Activates pro-inflammatory and pro-fibrotic responses in dermal fibroblasts and enhances wound healing probably via PAR-2/F2RL1-dependent mechanism .
PMID:18202198
Activates barrier protective signaling responses in endothelial cells in PAR-2/F2RL1-dependent manner; the activity depends on the cleavage of PAR-2/F2RL1 by factor Xa .
PMID:22409427
Up-regulates expression of plasminogen activator inhibitor 1 (SERPINE1) in atrial tissues PMID:24041930
PMID:10744784 PMID:12031666 PMID:12923223 PMID:9326939
Does not hydroxylate long and very long straight chain acyl-CoAs or 2-methyl- and 4-methyl-branched acyl-CoAs PMID:10744784 PMID:12923223
The receptor then returns to the cell membrane surface
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC B02BD02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Antihemophilic factor, human recombinant
Matched from: Octocog alfa
Additional database identifiers
Drugs Product Database (DPD)
745
Drugs Product Database (DPD)
9847
Drugs Product Database (DPD)
12787
Drugs Product Database (DPD)
22826
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3528
GenAtlas
F10
GeneCards
F10
GenBank Gene Database
K03194
GenBank Protein Database
182841
Guide to Pharmacology
2359
UniProt Accession
FA10_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3551
GenAtlas
F9
GeneCards
F9
GenBank Gene Database
K02402
GenBank Protein Database
182609
Guide to Pharmacology
2364
UniProt Accession
FA9_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12726
GenAtlas
VWF
GeneCards
VWF
GenBank Gene Database
X04385
GenBank Protein Database
37947
UniProt Accession
VWF_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8940
GenAtlas
PHYH
GeneCards
PHYH
GenBank Gene Database
AF023462
GenBank Protein Database
2564671
UniProt Accession
PAHX_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:743
GenAtlas
ASGR2
GeneCards
ASGR2
GenBank Gene Database
M11025
GenBank Protein Database
179081
UniProt Accession
ASGR2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5238
GenAtlas
HSPA5
GeneCards
HSPA5
GenBank Gene Database
M19645
GenBank Protein Database
386758
UniProt Accession
BIP_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1455
GenAtlas
CALR
GeneCards
CALR
GenBank Gene Database
M32294
GenBank Protein Database
337487
UniProt Accession
CALR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1473
GenAtlas
CANX
GeneCards
CANX
GenBank Gene Database
L10284
GenBank Protein Database
186523
UniProt Accession
CALX_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6631
GenAtlas
LMAN1
GeneCards
LMAN1
GenBank Gene Database
X71661
GenBank Protein Database
433938
UniProt Accession
LMAN1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6692
GenAtlas
LRP1
GeneCards
LRP1
GenBank Gene Database
X13916
GenBank Protein Database
34339
UniProt Accession
LRP1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:18451
GenAtlas
MCFD2
GeneCards
MCFD2
GenBank Gene Database
AF475284
GenBank Protein Database
20799383
UniProt Accession
MCFD2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3535
GenAtlas
F2
GeneCards
F2
GenBank Gene Database
M17262
GenBank Protein Database
339641
Guide to Pharmacology
2362
UniProt Accession
THRB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9451
GenAtlas
PROC
GeneCards
PROC
GenBank Gene Database
M11228
GenBank Protein Database
190334
Guide to Pharmacology
2396
UniProt Accession
PROC_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q6913198), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.